内容摘要：named Sprinkles. In this video, she’s having one of those days where her human is absolutely disrupting her peace of mind. And she’s decided to tell them about themselves in her own sassy way. Go ahead and watch this three-pound Yorkie give her human a scolding, and try not to laugh too much at this precious pup.

named Sprinkles. In this video, she’s having one of those days where her human is absolutely disrupting her peace of mind. And she’s decided to tell them about themselves in her own sassy way. Go ahead and watch this three-pound Yorkie give her human a scolding, and try not to laugh too much at this precious pup.

Emily Alimonti, a 42-year-old biotech salesperson in upstate New York, chose that path before starting capecitabine treatment in December. She said her doctors — including an oncologist at Sloan Kettering — told her they didn’t do deficiency testing, but Alimonti insisted. “Nope,” she said. “I’m not starting it until I get the test back.”The test showed that Alimonti had a copy of a risky gene variant, so doctors gave her a lower dose of the drug. Even that has been hard to tolerate; she’s had to skip doses because of low white blood cell counts, Alimonti said. She still doesn’t know whether her insurer will cover the test.

Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing a drug, however, U.S. regulators have little power to manage its use. And 5-FU and capecitabine are still powerful tools against many cancers.At a January workshop that included FDA officials and cancer specialists, Venook, the NCCN panel’s co-chair, asked whether it was reasonable to recommend that doctors obtain a genetic test “without saying what to do with the result.”But Richard Pazdur, the FDA’s top cancer expert, said it was time to end the debate and commence testing, even if the results could be ambiguous. “If you don’t have the information, how do you have counseling?” he asked.

Two months later, Venook’s panel changed course. The price of tests has fallen below $300 and results can be returned as soon as three days, Venook said. Doubts about the FDA’s ability to further confront the issue spurred the panel’s change of heart, he said.“I don’t know if FDA is going to exist tomorrow,” Venook told KFF Health News. “They’re taking a wrecking ball to common sense, and that’s one of the reasons we felt we had to go forward.”

On May 20, the FDA posted a

seeking public input on the issue, a move that suggested it was considering further action.Asian-Americans and native Hawaiians did not show as pronounced of a risk reduction.

The longer people adhered to the diet, the greater the reduction of risk. Those who followed the plan over a 10-year period had a 25% lower risk compared to those who didn’t stick with it."Our study findings confirm that

in mid to late life and their improvement over time may prevent Alzheimer’s and related dementias," said Song-Yi Park, PhD, associate professor at the University of Hawaii at Manoa, in the release."This suggests that it is never too late to adopt a